A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
At a glance
- Drugs Intepirdine (Primary)
- Indications Lewy body disease
- Focus Registrational; Therapeutic Use
- Acronyms HEADWAY-DLB
- Sponsors Axovant Sciences
- 12 May 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jan 2017 According to an Axovant Sciences media release, results from the study are expected in the fourth quarter of 2017.
- 23 Feb 2016 According to Axovant media release, data from this trial will be presented at the Cowen and Company 36th Annual Health Care Conference on March 8.